Industry

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September. Cantor Global Healthcare Conference 2025Date/Time: Friday, September 5, 7:00 a.m. ET H.C. Wainwright & Co. … [Read more…]

Hammes Partners announced the closing of $445 million in equity commitments for its core-plus healthcare real estate platform —building on a history of institutional investment in healthcare real estate. MILWAUKEE–(BUSINESS WIRE)–Hammes Partners, one of the leading institutional investment management firms focused on the U.S. healthcare real estate market, announced the successful closing of $445 million … [Read more…]

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma. There is currently no approved treatment for patients with primary vitreoretinal lymphoma, a rare, … [Read more…]

VENLO, Netherlands–(BUSINESS WIRE)–$QGEN #QIAGEN—NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. … [Read more…]

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each share of common stock is being sold at a public offering price of $9.00 per share. Total gross proceeds from the … [Read more…]

VIENNA, Va.–(BUSINESS WIRE)–$CVM #Multikine–CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in a best-efforts public offering. All of the shares of common stock (and/or Pre-Funded Warrants) … [Read more…]

Clinician demand and patient need driving adoption of genetic optimization software, giving IVF families unprecedented insight before embryo transfer BEVERLY HILLS, Calif. & NEW YORK–(BUSINESS WIRE)–Nucleus Genomics and Beverly Hills Fertility announced an exclusive collaboration to offer Nucleus Embryo, the industry’s first genetic optimization software, to parents at Beverly Hills Fertility. Research shows growing interest … [Read more…]

LAVAL, Québec–(BUSINESS WIRE)–#AI—Altasciences, a fully integrated CRO/CDMO offering comprehensive early-phase drug development solutions, is pleased to announce a strategic collaboration with Evidence Matters, a pioneer in clinical trial data science and document engineering. This partnership combines Altasciences’ real-world drug development expertise with Evidence Matters’ innovative, patent-pending Text Engineering technology—a breakthrough that delivers near-deterministic accuracy in … [Read more…]

Combined company creates transformational omnichannel member engagement platform LOS ANGELES–(BUSINESS WIRE)–mPulse, a leading provider of Health Experience and Insights (HXI) technology, today announced it has acquired Clarity Software Solutions, a leader in health communications technology for the production of critical member-journey touchpoints through personalized, intelligent cross-channel engagement. The need for health plans to adopt technologies … [Read more…]

ASHBURN, Va.–(BUSINESS WIRE)–I2Pure and Caracal Products & Services, through its Caracal Healthcare Products division, today announce an expansion of their relationship. I2Pure’s proprietary iodine formulations and product concepts have received an overwhelmingly favorable response from Caracal’s healthcare customer base. Based on that positive feedback, I2Pure and Caracal have committed joint efforts to accelerate manufacturing and … [Read more…]